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Dear Editor, 
Rose et al. conducted the randomized controlled trial “Magnesium supplementation in the 
treatment of Pseudoxanthoma Elasticum (PXE)”1 that  we read with great interest. Indeed, 
magnesium is effective against elastic tissue calcification in PXE mouse models1. However, 
in this study, we regret that magnesium treatment results only in a trend towards 
improvement1. So, various factors may account for lack of statistical effect beyond a small 
sample size. Magnesium supplements or magnesium-salt, a combination of magnesium and 
other minerals, come in four different forms: i) insoluble inorganic-salts (oxide-carbonate-
hydroxide); ii) soluble inorganic-salts (chloride-sulfate); iii) soluble organic-salts (citrate-
lactate-gluconate); and iv) soluble organic complexes (glycinate-bisglycinate)2. Importantly, 
magnesium-element amount is depending from its form2. Magnesium bioavailability 
corresponding to the absorbed quantity is the most relevant pharmacological parameter in 
magnesium-salt selection2. The authors used magnesium-oxide, one of the cheapest available 
salts, with a relatively high content in magnesium, but with a low bioavailability2. Indeed, 
excessively high magnesium content may have a laxative effect. Hence, the necessity for 
dose-splitting2. Magnesium-citrate has the highest bioavailability of all magnesium-salts, 
compared to chelated forms and magnesium-oxide2. In a randomized, placebo-controlled 
study 46 healthy subjects received daily 300 mg doses of magnesium-citrate or magnesium-
oxide3. Saliva, blood, and 24-hour urine samples were taken at baseline, 24-hours and 60-
days3. At 60-days urinary magnesium excretion was higher with magnesium-citrate than with 
magnesium-oxide. Magnesium-citrate induced higher mean serum magnesium concentration 
than magnesium-oxide following 24-hour (p=0.026) and 60-day (p=0.006) supplementation3. 
This study showed that magnesium-citrate is more soluble than magnesium-oxide3, hence its 
higher absorption rate as demonstrated by higher plasma concentration and urinary excretion 
outcomes than magnesium-oxide at various time-points after administration3. Thus available 
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data suggest that magnesium-citrate is better suited to therapeutic and supplementary use3. 
Furthermore citric acid, as a low molecular weight organic acid, promotes magnesium 
absorption by increasing its solubility3,4. Additionally, citrate is a major substrate in cellular 
energy metabolism and other cellular processes, binding calcium and inhibiting nucleation 
and calcium crystal growth4 which is the desired outcome for PXE. A recent study found that 
citrate inhibited calcification in CKD patient urine4. Also, potassium-magnesium-citrate is an 
effective prophylaxis against recurrent calcium-oxalate nephrolithiasis4, a complication 
frequently observed in PXE patients. Furthermore, magnesium-citrate has been shown in a 
recent study to protect against vascular calcification in an adenine-induced chronic renal 
failure rat model4. 
Magnesium should remain a new treatment way for PXE calcification, yet larger studies are 
required. We suggest considering magnesium-citrate, the highest bioavailable magnesium-salt 
for treatment of PXE calcification, in future clinical trials. Since vascular calcification is a 
well‐known predictive risk factor of subsequent cardiovascular mortality5, changes in vascular 
calcification could constitute a trial endpoint.  
Magnesium balance in PXE patients should additionally constitute a secondary endpoint. 
Therefore, serum magnesium concentration, red-blood cell magnesium concentration and 24-
hours urinary magnesium excretion are potentially useful biomarkers of magnesium status5.  
Given the rarity of PXE and the few patients involved, it is time to combine efforts for a cure 
and we call for international multicenter trials encompassing all PXE patient associations.  
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